Teerlink, J. R., Felker, G. M., Solomon, S. D., Niegowska, J., Szachniewicz, J., Tomcsanyi, J., … Malik, F. I. (2017). Treatment With Omecamtiv Mecarbil, a Cardiac Myosin Activator, Improves NT-proBNP in Patients With Chronic Heart Failure: A Responder Analysis From COSMIC-HF. In CIRCULATION (Vol. 136).

Teerlink, John R., G Michael Felker, Scott D. Solomon, Joanna Niegowska, Joanna Szachniewicz, Janos Tomcsanyi, Craig S. Barr, James T. Johnston, Gustavo L. Buchele, and Fady I. Malik. “Treatment With Omecamtiv Mecarbil, a Cardiac Myosin Activator, Improves NT-proBNP in Patients With Chronic Heart Failure: A Responder Analysis From COSMIC-HF.” In CIRCULATION, Vol. 136, 2017.

Teerlink JR, Felker GM, Solomon SD, Niegowska J, Szachniewicz J, Tomcsanyi J, et al. Treatment With Omecamtiv Mecarbil, a Cardiac Myosin Activator, Improves NT-proBNP in Patients With Chronic Heart Failure: A Responder Analysis From COSMIC-HF. In: CIRCULATION. 2017.

Teerlink, John R., et al. “Treatment With Omecamtiv Mecarbil, a Cardiac Myosin Activator, Improves NT-proBNP in Patients With Chronic Heart Failure: A Responder Analysis From COSMIC-HF.” CIRCULATION, vol. 136, 2017.

Teerlink JR, Felker GM, Solomon SD, Niegowska J, Szachniewicz J, Tomcsanyi J, Barr CS, Johnston JT, Buchele GL, Malik FI. Treatment With Omecamtiv Mecarbil, a Cardiac Myosin Activator, Improves NT-proBNP in Patients With Chronic Heart Failure: A Responder Analysis From COSMIC-HF. CIRCULATION. 2017.